新辅助早期立体定向体部放疗联合化疗免疫治疗用于交界可切除及局部晚期胰腺癌
这项单中心前瞻性试验纳入22例初治交界可切除或局部晚期胰腺癌患者,分入早期SBRT(25 Gy/5次)后行白蛋白紫杉醇+吉西他滨+卡瑞利珠单抗组或不加SBRT的单纯化疗免疫治疗组。总客观缓解率36.4%,疾病控制率100%,6例(27.3%)接受手术且均达R0切缘与病理降期;探索性分析示SBRT组中位无进展生存12.5个月 vs 6.6个月(P=.003),总生存无显著差异,≥3级治疗相关不良事件36.4%。
要点
- 早期SBRT联合化疗免疫治疗在BRPC/LAPC中显示36.4%客观缓解率和100%疾病控制率。
- 6例(27.3%)接受手术者均实现临床至病理降期及R0切缘。
- 探索性分析SBRT组中位PFS 12.5个月优于非SBRT组6.6个月(P=.003)。
核心结论
- 新辅助白蛋白紫杉醇+吉西他滨+卡瑞利珠单抗联合或不联合早期SBRT在BRPC/LAPC中显示令人鼓舞的疗效和可接受的耐受性。
- 早期SBRT的潜在获益值得进一步研究。
研究设计与样本
- 单中心前瞻性试验,纳入22例既往未治疗的成人BRPC/LAPC患者,SBRT组与非SBRT组各11例。
- SBRT组接受早期SBRT 25 Gy分5次,随后白蛋白紫杉醇125 mg/m2+吉西他滨1000 mg/m2(第1、8天)联合卡瑞利珠单抗200 mg每3周;非SBRT组仅接受相同化疗免疫治疗。
- 由多学科团队决定患者是否接受手术或继续一线治疗,主要终点为客观缓解率。
主要发现
- 总客观缓解率为36.4%(8/22),疾病控制率为100%(22/22)。
- 6例(27.3%)接受手术,均实现临床至病理降期及R0切缘(6/6)。
- 中位随访30.0个月(95% CI,23.3-36.7),探索性组间分析示SBRT组中位无进展生存12.5个月(95% CI,9.6至不可评估),非SBRT组6.6个月(95% CI,6.4至不可评估),P=.003。
- SBRT组和非SBRT组中位总生存分别为20.8个月和13.9个月(P=.261)。
- 两组毒性特征相似,≥3级治疗相关不良事件发生率为36.4%。
关键数值与推荐
- SBRT剂量为25 Gy分5次。
- 白蛋白紫杉醇125 mg/m2联合吉西他滨1000 mg/m2于第1、8天给药,卡瑞利珠单抗200 mg每3周。
- 主要终点客观缓解率36.4%(8/22),疾病控制率100%(22/22)。
- 手术转化率27.3%(6/22),R0切缘率6/6。
- ≥3级治疗相关不良事件发生率36.4%。
临床怎么用
- 对于BRPC/LAPC,可考虑新辅助白蛋白紫杉醇+吉西他滨+卡瑞利珠单抗联合早期SBRT方案,需多学科团队评估手术时机。
- 早期SBRT可能改善无进展生存,但总生存获益未证实,应作为研究性策略谨慎使用。
局限性
- 单中心、小样本(22例),两组各11例。
- 组间无进展生存比较为探索性分析。
- 总生存差异无统计学意义(P=.261)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal neoadjuvant therapy for borderline resectable pancreatic cancer/locally advanced pancreatic cancer (BRPC/LAPC) remains undefined. This study evaluated the efficacy and safety of neoadjuvant nab-paclitaxel and gemcitabine plus camrelizumab, with or without early stereotactic body radiation therapy (SBRT), among patients with BRPC/LAPC. METHODS AND MATERIALS: This single-center, prospective trial enrolled adults with previously untreated BRPC/LAPC. Patients were assigned to an SBRT cohort, receiving early SBRT (25 Gy in 5 fractions) followed by nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) on days 1 and 8 with camrelizumab (200 mg every 3 weeks), or to a non-SBRT cohort treated with the same chemoimmunotherapy alone. A multidisciplinary team determined whether patients underwent surgery or continued first-line therapy. The objective response rate served as the primary endpoint. RESULTS: A total of 22 patients were enrolled (11 in each cohort). The objective response rate was 36.4% (8/22), and disease-control rate was 100% (22/22). Six patients (27.3%) underwent surgery, and all achieved clinical-to-pathologic downstaging and R0 margins (6/6). With a median follow-up of 30.0 months (95% CI, 23.3-36.7), median progression-free survival was 12.5 months (95% CI, 9.6 to not available) in the SBRT cohort and 6.6 months (95% CI, 6.4 to not available) in the non-SBRT cohort in an exploratory between-cohort analysis (P = .003). Median overall survival was 20.8 and 13.9 months in the SBRT and non-SBRT cohorts, respectively (P = .261). Toxicity profiles were similar across cohorts, with grade ≥3 treatment-related adverse events occurring in 36.4% of patients. CONCLUSIONS: Neoadjuvant nab-paclitaxel and gemcitabine plus camrelizumab, with or without early SBRT, showed encouraging efficacy and acceptable tolerability for BRPC/LAPC. The potential benefit of early SBRT warrants further investigation.
引用
- Zhao S, Tang J, Li X, et al. Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Adv Radiat Oncol. 2026. PMID: 42571456. doi:10.1016/j.adro.2026.102128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。